Valerio Therapeutics: directors' dealings · France · AMF

About Valerio Therapeutics

Valerio Therapeutics S.A. is a French biotechnology company listed on Euronext Growth Paris under the ticker ALVIO and ISIN FR0010095596. Headquartered in Villejuif, in the greater Paris area, the company is focused on next-generation precision-guided therapeutics designed to address complex and underserved diseases. Valerio Therapeutics was built on the legacy of Onxeo, and adopted its current name following approval at the Annual General Meeting of June 6, 2023. Since then, the group has progressively reshaped its strategy toward a broader discovery and early-development model. That repositioning was further reinforced in 2025 through a substantial portfolio review and a sharper focus on preclinical activities. Historically, the company was centered on oncology and DNA Damage Response (DDR), with assets such as AsiDNA and VIO-01. However, in February 2025 Valerio Therapeutics announced the discontinuation of all clinical trials and related activities, including the ongoing VIO-01 study, in order to concentrate resources on preclinical research and the development of proprietary technology platforms. This strategic shift reflects a disciplined capital-allocation approach, prioritizing scientific value creation before clinical entry. Today, the company’s business model rests on two complementary proprietary platforms: V-Body and an integrated chemistry platform. V-Body is based on fully synthetic, humanized single-domain antibody libraries (sdAbs), designed to deliver high specificity, stability and versatility. These small-format biologics can be used in multiple modalities, including antibody-drug conjugates (ADCs), bispecific T-cell engagers (BiTEs), CAR-T sdAbs and oligonucleotide conjugates. The chemistry platform complements this biology engine by enabling the design and synthesis of hybrid molecules and immunoconjugates that combine biological targeting with chemical payload delivery. From a market perspective, Valerio Therapeutics is expanding beyond its historical oncology focus into autoimmune, inflammatory and rare diseases. The company is pursuing a partnership-driven strategy, seeking out licensing, co-development and industrial collaborations to monetize assets earlier in the development cycle. In 2024, it created Valour Bio to consolidate its single-domain antibody efforts and acquired Emglev Therapeutics, a spin-off from Institut Curie, to strengthen its scientific capabilities in sdAb discovery. Geographically, the company remains mainly based in France, with its operational center in Villejuif, although it has historically maintained an international footprint through clinical and partnering activities. Recent notable events include the publication of its 2025 half-year financial report, the completion of the merger with Valour Bio in December 2025, and the continued execution of a financing strategy aimed at supporting preclinical milestones. Overall, Valerio Therapeutics is a specialty biotech in transition, leveraging proprietary science, intellectual property and strategic partnerships to rebuild long-term value.